Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: William Whitehead Jr. who wrote (627)	5/5/1999 9:47:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

I don't think the Company is "presenting" anything. There is going to be a paper presented at the ASCO conference in San Diego on May 15th mentioning the use of Theratope vaccine in some cases of breast cancer after they had been previously treated with chemotherapy and bone marrow transplants. I believe there is also some report about the "bridging study" where they are treating about 18 patients with the newer, more potent formulation of the vaccine, just apparently to make sure there is no increased toxicity. They already got the OK from the FDA to use the new formulation without having to repeat the Phase II. I was able to pick-up another 6000 shares this week around 4 1/8, but my average cost is still less than 3. Good luck. Bernard